Lv1
28 积分 2025-01-03 加入
Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies
21小时前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
22小时前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
22小时前
已完结
Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure
1天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1天前
已完结
TROP-2–directed antibody–drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes
1天前
已完结
Trastuzumab Rezetecan: First Approval
2天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
2天前
已完结
Disitamab Vedotin: First Approval
2天前
已完结
皖公网安备34019202002308
